

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 December 2023 (07.12.2023)



(10) International Publication Number

WO 2023/232764 A1

(51) International Patent Classification:

A61K 31/5415 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/EP2023/064369

(22) International Filing Date:

30 May 2023 (30.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2208038.6 31 May 2022 (31.05.2022) GB
2214646.8 05 October 2022 (05.10.2022) GB

(71) Applicant: **WISTA LABORATORIES LTD.** [SG/SG];
25 Bukit Batok Crescent, The Elitist, #06-13, Singapore
658066 (SG).

(72) Inventor; and

(71) Applicant (for MG only): **WISCHIK, Claude Michel**
[GB/GB]; TauRx Therapeutics Ltd., 395 King Street, Ab-
erdeen Aberdeenshire AB24 5RP (GB).

(72) Inventors: **STOREY, John Mervyn David**; WisTa Lab-
oratories Ltd., Department of Chemistry, Meston Walk,
Old Aberdeen, Aberdeen Aberdeenshire AB24 3UE (GB).
SCHELTER, Björn Olaf; TauRx Therapeutics Ltd., 395
King Street, Aberdeen Aberdeenshire AB24 5RP (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS

(57) Abstract: The invention provides methods of treatment of a neurodegenerative disease in a subject, which methods comprise orally administering to said subject a methylthioninium (MT) containing compound, wherein said administration is at a dosage frequency of less than once daily; and wherein said administration provides an amount of MT to the subject that corresponds to an average of between 0.05 mg and 30 mg MT per day, preferably between 0.1 mg and 20 mg MT per day. The invention further provides related compositions and kits of parts for use in the method.

WO 2023/232764 A1